Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 3/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL107180 | 0.83 | TRPA1 (0.67) | TAAR1SLC6A2TRPA1ACEMME | |
| SCHEMBL109936 | 0.82 | TAAR1 (0.55) | ESR1ESR2TAAR1SLC6A2ADRB2 | |
| SCHEMBL1695818 | 0.81 | TRPA1 (0.69) | ESR1ESR2TAAR1SLC6A2TRPA1 | |
| SCHEMBL107120 | 0.80 | ESR1 (0.57) | ESR1ESR2TAAR1SLC6A2TRPA1 | |
| SCHEMBL28097034 | 0.80 | TAAR1 (0.57) | ESR1ESR2TAAR1SLC6A2TRPA1 | |
| SCHEMBL17191622 | 0.78 | TAAR1 (0.59) | ESR1ESR2TAAR1SLC6A2ADRB2 | |
| SCHEMBL107844 | 0.78 | TAAR1 (0.59) | ESR1ESR2TAAR1SLC6A2ADRB2 | |
| SCHEMBL15928032 | 0.77 | TAAR1 (0.56) | ESR1ESR2TAAR1SLC6A2 | |
| SCHEMBL450874 | 0.77 | TAAR1 (0.56) | ESR1ESR2TAAR1SLC6A2 | |
| SCHEMBL20673668 | 0.75 | TAAR1 (0.67) | ESR1ESR2TAAR1SLC6A2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463374-A2 | Isolated alcohol dehydrogenase enzymes and uses thereof | Bio Architecture Lab, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2195440-A2 | BIOFUEL PRODUCTION | Bio Architecture Lab, Inc. (US) | 2010-06-16 | — | — | EP | claimed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | claimed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | claimed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| EP-3230463-B2 | RAPID PRETREATMENT | APALTA PATENTS OUE (EE) | 2025-07-16 | — | — | EP | disclosed |
| US-20240425893-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2024-12-26 | — | — | US | disclosed |
| US-12054761-B2 | Rapid pretreatment | Apalta Patents OÜ (EE) | 2024-08-06 | — | — | US | disclosed |
| US-11821047-B2 | High pressure zone formation for pretreatment | Apalta Patent OÜ (EE) | 2023-11-21 | — | — | US | disclosed |
| US-20230295678-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2023-09-21 | — | — | US | disclosed |
| EP-4098750-A1 | RAPID PRETREATMENT | Sweetwater Energy, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3230463-B1 | RAPID PRETREATMENT | SWEETWATER ENERGY INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20100086981-A1 | COMPOSITIONS AND METHODS FOR IMPROVED SACCHARIFICATION OF BIOMASS | QTEROS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20090203089-A1 | ISOLATED ALCOHOL DEHYDROGENASE ENZYMES AND USES THEREOF | BIO ARCHITECTURE LAB, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2009097346-A2 | ISOLATED ALCOHOL DEHYDROGENASE ENZYMES AND USES THEREOF | BIO ARCHITECTURE LAB, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090139134-A1 | BIOFUEL PRODUCTION | MGAM, DCXR, MANBA | ESR1 3581/4885ESR2 3683/4885TAAR1 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.